CN106999590A - 免疫检查点抑制剂在中枢神经系统肿瘤中的用途 - Google Patents

免疫检查点抑制剂在中枢神经系统肿瘤中的用途 Download PDF

Info

Publication number
CN106999590A
CN106999590A CN201580069022.6A CN201580069022A CN106999590A CN 106999590 A CN106999590 A CN 106999590A CN 201580069022 A CN201580069022 A CN 201580069022A CN 106999590 A CN106999590 A CN 106999590A
Authority
CN
China
Prior art keywords
antibody
antigen
binding portion
administered
ctla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580069022.6A
Other languages
English (en)
Chinese (zh)
Inventor
V.科里奇
郑新达
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN106999590A publication Critical patent/CN106999590A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201580069022.6A 2014-12-16 2015-12-16 免疫检查点抑制剂在中枢神经系统肿瘤中的用途 Pending CN106999590A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462092783P 2014-12-16 2014-12-16
US62/092,783 2014-12-16
US201562261130P 2015-11-30 2015-11-30
US62/261,130 2015-11-30
PCT/US2015/066177 WO2016100561A2 (en) 2014-12-16 2015-12-16 Use of immune checkpoint inhibitors in central nervous systems neoplasms

Publications (1)

Publication Number Publication Date
CN106999590A true CN106999590A (zh) 2017-08-01

Family

ID=56127849

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580069022.6A Pending CN106999590A (zh) 2014-12-16 2015-12-16 免疫检查点抑制剂在中枢神经系统肿瘤中的用途

Country Status (9)

Country Link
US (3) US20180133313A1 (https=)
EP (1) EP3233123A4 (https=)
JP (2) JP2018500332A (https=)
CN (1) CN106999590A (https=)
BR (1) BR112017010101A2 (https=)
CA (1) CA2969338A1 (https=)
MX (1) MX2017007390A (https=)
RU (1) RU2726996C1 (https=)
WO (1) WO2016100561A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111971306A (zh) * 2018-03-30 2020-11-20 百时美施贵宝公司 治疗肿瘤的方法
CN112203688A (zh) * 2018-05-31 2021-01-08 小野药品工业株式会社 用于确定免疫检查点抑制剂的有效性的生物标志物
CN114340667A (zh) * 2019-09-10 2022-04-12 诺沃库勒有限责任公司 通过向癌细胞施加交变电场和给予检查点抑制剂来降低癌细胞生存能力的方法
CN115135386A (zh) * 2019-12-19 2022-09-30 得克萨斯州大学系统董事会 用于治疗胶质母细胞瘤的方法
CN115697374A (zh) * 2020-05-12 2023-02-03 得克萨斯州大学系统董事会 用于治疗胶质母细胞瘤的方法

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
MY184154A (en) 2013-12-12 2021-03-23 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
EP3288982A1 (en) 2015-04-28 2018-03-07 Bristol-Myers Squibb Company Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody
US20160362489A1 (en) * 2015-04-28 2016-12-15 Bristol-Myers Squibb Company Treatment of PD-L1-Positive Melanoma Using an Anti-PD-1 Antibody
MA44594B1 (fr) 2015-05-29 2020-09-30 Memorial Sloan Kettering Cancer Center Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
KR102055396B1 (ko) 2015-08-11 2019-12-12 우시 바이올로직스 (케이만) 인코포레이티드 신규한 항-pd-1 항체
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
WO2017176925A1 (en) 2016-04-05 2017-10-12 Bristol-Myers Squibb Company Cytokine profiling analysis for predicting prognosis of a patient in need of an anti-cancer treatment
WO2018029124A1 (en) * 2016-08-08 2018-02-15 F. Hoffmann-La Roche Ag Therapeutic and diagnostic methods for cancer
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
GB201618291D0 (en) * 2016-10-28 2016-12-14 Bergen Teknologioverf�Ring As Novel immunotherapeutic treatments for tumours
IL303038B2 (en) 2016-12-05 2024-08-01 G1 Therapeutics Inc Preservation of immune response during chemotherapy regimens
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
JP7106538B2 (ja) 2016-12-07 2022-07-26 アジェナス インコーポレイテッド 抗体およびその使用方法
DE102017119868B4 (de) * 2017-07-12 2021-05-27 Bruker Daltonik Gmbh Feuchtestabilisierung bei der Präparation von Proben für die Spektrometrie
JP7159007B2 (ja) * 2017-11-01 2022-10-24 小野薬品工業株式会社 脳腫瘍の治療のための医薬
EP3941467A4 (en) * 2019-03-19 2022-12-21 ChemoCentryx, Inc. MULTIPLE THERAPY USING A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1 AND/OR PD-L1 INHIBITOR
EP4082577A4 (en) * 2019-12-27 2024-01-03 Zeria Pharmaceutical Co., Ltd. CANCER TREATMENT METHOD AND DRUG
AR122043A1 (es) * 2020-05-12 2022-08-03 Bristol Myers Squibb Co Dosificación y administración del anticuerpo anti-ctla-4 activable
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022032312A1 (en) * 2020-08-07 2022-02-10 Northwestern University Methods of treating malignant glioblastoma

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055102A1 (en) * 2008-08-25 2010-03-04 Solomon Langermann Compositions of pd-1 antagonists and methods of use
WO2012177624A2 (en) * 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101814408B1 (ko) * 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
RU2402360C1 (ru) * 2009-07-08 2010-10-27 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ лечения злокачественной глиомы головного мозга
CN102178676B (zh) * 2011-04-29 2012-07-25 山东大学 一种治疗脑胶质瘤的药物组合物
CN113967253A (zh) * 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US10392442B2 (en) * 2015-12-17 2019-08-27 Bristol-Myers Squibb Company Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100055102A1 (en) * 2008-08-25 2010-03-04 Solomon Langermann Compositions of pd-1 antagonists and methods of use
WO2012177624A2 (en) * 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
CN103796680A (zh) * 2011-06-21 2014-05-14 约翰霍普金斯大学 用于增强针对赘生物的基于免疫的治疗的聚焦放射

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV ARCHIVE: "A Randomized Study of Nivolumab Versus Bevacizumab and a Safety Study of Nivolumab or Nivolumab Combined With Ipilimumab in Adult Subjects With Recurrent Glioblastoma (GBM) (CheckMate 143)", 《CLINICALTRIALS.GOV ARCHIVE》 *
JEDD D. WOLCHOK等: "Nivolumab plus ipilimumab in advanced melanoma", 《THE NEW ENGLAND JOURNAL OF MEDICINE》 *
JOHN HOWARD SAMPSON等: "Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM)", 《JOURNAL OF CLINICAL ONCOLOGY》 *
SHIAO-PEI WEATHERS等: "Advances in treating glioblastoma", 《F1000PRIMER REPORTS》 *
周菊英等: "《肿瘤放射治疗学（第三版）》", 31 July 2014, 中国原子能出版社 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111971306A (zh) * 2018-03-30 2020-11-20 百时美施贵宝公司 治疗肿瘤的方法
CN112203688A (zh) * 2018-05-31 2021-01-08 小野药品工业株式会社 用于确定免疫检查点抑制剂的有效性的生物标志物
US12240903B2 (en) 2018-05-31 2025-03-04 Ono Pharmaceutical Co., Ltd. Biomarkers for determining the effectiveness of immune checkpoint inhibitors
CN114340667A (zh) * 2019-09-10 2022-04-12 诺沃库勒有限责任公司 通过向癌细胞施加交变电场和给予检查点抑制剂来降低癌细胞生存能力的方法
CN115135386A (zh) * 2019-12-19 2022-09-30 得克萨斯州大学系统董事会 用于治疗胶质母细胞瘤的方法
CN115697374A (zh) * 2020-05-12 2023-02-03 得克萨斯州大学系统董事会 用于治疗胶质母细胞瘤的方法

Also Published As

Publication number Publication date
JP2018500332A (ja) 2018-01-11
WO2016100561A2 (en) 2016-06-23
US20240238416A1 (en) 2024-07-18
BR112017010101A2 (pt) 2018-01-02
EP3233123A2 (en) 2017-10-25
US20180133313A1 (en) 2018-05-17
WO2016100561A3 (en) 2016-08-18
CA2969338A1 (en) 2016-06-23
EP3233123A4 (en) 2018-05-09
MX2017007390A (es) 2017-11-06
US20210000953A1 (en) 2021-01-07
RU2726996C1 (ru) 2020-07-17
JP2021181482A (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
US20240238416A1 (en) Use of immune checkpoint inhibitors in central nervous systems neoplasms
US11274152B2 (en) Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
US20250197495A1 (en) Anti-lag-3 antibodies to treat hematological malignancies
JP2022513685A (ja) 養子細胞療法を用いた処置のための方法
CN108602892A (zh) 使用抗-pd-1抗体和另一种抗癌剂的组合治疗肺癌
JP7308190B2 (ja) 抗ｃｄ４７及び抗ｐｄ－ｌ１による卵巣癌の処置
KR20190008962A (ko) 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도
EP4559477A2 (en) Compositions and methods for treating cancer
CN114206346A (zh) 施用嵌合抗原受体免疫疗法的方法
AU2020380384A1 (en) LAG-3 antagonist therapy for melanoma
JP2025522729A (ja) ガレクチン－９を阻害する抗体を用いた悪性血液疾患の処置
AU2022266821A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
JP2023523450A (ja) 非小細胞肺がん免疫療法のための方法及び組成物
EP4423135A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
HK40070586A (en) Methods of administering chimeric antigen receptor immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination